Source: International Congress 2019 – Lung transplantation: from basic science to clinical outcomes
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Carrillo Hernández-Rubio (Majadahonda, Spain), S. Aguado Ibañez (Majadahonda, Spain), R. Laporta Hernández (Majadahonda, Spain), M. Ussetti Gil (Majadahonda, Spain). Impact of antifibrotic drugs in lung transplantation. 3366

Member's Comments

No comment yet.

Related content which might interest you: Safety of antifibrotic drugs in idiopathic pulmonary fibrosis patients awaiting lung transplantation Source: International Congress 2018 – Moving lung transplantation forward Year: 2018 New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? Source: Virtual Congress 2020 – Lung transplantation in the era of new drugs Year: 2020 Evaluation of the biological effects of atorvastatin in lung transplant recipients Source: Annual Congress 2007 - New insights into clinical lung transplantation Year: 2007 Immunosuppressive therapy after human lung transplantation Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=105 Year: 2003 How to use new immunosuppressive drugs in lung transplantation Source: Annual Congress 2006 - MP5 – How to use new immunosuppressive drugs in lung transplantation Year: 2006 Lung transplantation for pulmonary hypertension: the impact of new drug therapies Source: Annual Congress 2004 - Lung transplantation: new insights in advanced lung disease and new drug developments - do they impact on selection criteria? Year: 2004 Immunosuppressive therapy after human lung transplantation Source: Eur Respir J 2004; 23: 159-171 Year: 2004 The influence of different immunosuppressive regimen on non-mnestic cognitive functions in patients after lung transplantation Source: International Congress 2014 – Maximise lung transplant outcomes: pre- and post-operative issues Year: 2014 Negative consequences of immunosuppressive therapy on bronchial healing following lung transplantation (LTx) Source: Annual Congress 2013 –Clinical studies in lung transplantation Year: 2013 Update on lung transplantation Source: Annual Congress 2013 –Ceremony for ERS Research Award on Idiopathic Pulmonary Fibrosis (financially supported by InterMune) followed by Clinical Year in Review I Year: 2013 Early sirolimus immunosuppression is safe in lung transplantation Source: Annual Congress 2012 - Optimising outcomes after lung transplantation Year: 2012 Infectious complications after lung transplantation Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=193 Year: 2003 The effect of everolimus on lung function and renal status in lung transplanted patients Source: International Congress 2016 – Post-transplant complications: from animal models to the bedside Year: 2016 Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Benefit of pulmonary rehabilitation in candidates for lung transplantation Source: Annual Congress 2011 - Improving outcomes after lung transplantation Year: 2011 Airway cellular response to two different immunosuppressive regimens in lung transplant recipients Source: Eur Respir J 2004; 24: Suppl. 48, 466s Year: 2004 Anti-inflammatory effects of targeted lung denervation in patients with COPD Source: Eur Respir J 2015; 46: 1489-1492 Year: 2015 Medical complications of lung transplantation Source: Eur Respir J 2004; 23: 334-342 Year: 2004 Effects of two immunosuppressive triple therapies on inflammatory cells in lung Source: International Congress 2014 – Novel approaches in the management of lung transplant candidates and recipients Year: 2014 Effect of TLI during azithromycin treatment in patients with BOS after lung transplantation Source: Eur Respir J 2007; 30: Suppl. 51, 174s Year: 2007